Which pneumococcal vaccinations are effective for prevention of infection and mortality in asplenic patients?
Metadata[+] Show full item record
Which pneumococcal vaccinations are effective for prevention of infection and mortality in asplenic patients? EVIDENCE-BASED ANSWER: The time from vaccination and the patient’s antibody response may be more important than the vaccine type. In asplenic patients, vaccination with pneumococcal conjugate vaccine 7 (PCV7) administered in the last 5 years appears to lead to better survival rates than PCV7 administered more than 5 years ago or pneumococcal polysaccharide vaccine 23 (PPSV23) administered more than 7 years ago. This finding correlates with better antibody levels in recent vaccine recipients (SOR: B, cohort study). About a quarter of splenectomized patients show poor antibody response to PPSV23 vaccination, which appears to lead to less protection against overwhelming postsplenectomy infection (OPSI) than good antibody response (SOR: C, disease-oriented cohort study).
Evidence-based practice 19, no. 12 (2016): E7-E8